Press release no 691 – The Italian Medicines Agency has published the eleventh Pharmacovigilance Report on anti-COVID-19 vaccines. The data collected and analysed concern the reports of suspected adverse reactions registered in the National Pharmacovigilance Network between 27 December 2020 and 26 March 2022 for the five vaccines in use in the current vaccination campaign.
In the period considered, 134,361 reports were received out of a total of 135,849,988 doses administered (reporting rate of 99 per 100,000 doses), of which 82.1
Reporting rates for the 2nd dose are lower than for the 1st and even lower for the 3rd dose. The population exposed to the 4th dose is still limited. Serious reports correspond to 17.8
Comirnaty is currently the most used vaccine in the Italian vaccination campaign (65.2
For all vaccines, the most reported adverse events are fever, fatigue, headache, muscle/joint pain, chills, gastrointestinal upset, vegetative reactions, fatigue, local reaction or pain at the injection site. In the age group 5-11 years, as of 26/03/2022 a total of 439 reports (about 0.3
Source: https://www.aifa.gov.it
